pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine

BIOLOGICAL3 trials

Conditions

Fallopian Tube CarcinomaOvarian CarcinomaPrimary Peritoneal CarcinomaStage III Fallopian Tube CancerStage III Ovarian CancerStage III Ovarian Epithelial CancerStage III Ovarian Germ Cell TumorStage III Primary Peritoneal Cancer

Phase 1

Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer

CompletedNCT01322802

University of WashingtonStage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Ovarian Epithelial Cancer +1

Start: 2012-03-06End: 2020-12-01Updated: 2021-02-25

Phase 2

IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery

TerminatedNCT03029611

University of WashingtonStage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer +12

Start: 2017-04-03End: 2019-12-10Updated: 2022-01-14

IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence

RecruitingNCT07495124

University of WashingtonFallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma

Start: 2026-09-01End: 2028-09-30Target: 26Updated: 2026-08-06

Cancer Research2024-03-221 citations

817 AST-201 (pUMVC3-hIGFBP2 N-terminus) demonstrates anti-tumor effect in an ovarian cancer mouse model

Regular and Young Investigator Award Abstracts2023-10-312 citations

Phase II study of neoadjuvant IGFBP-2 vaccination with neoadjuvant carboplatin and paclitaxel in advanced ovarian cancer.

Journal of Clinical Oncology2018-05-202 citations

Vaccination targeting insulin-like growth factor binding protein-2 (IGFBP-2) in advanced ovarian cancer: Safety and immunogenicity.

Journal of Clinical Oncology2016-05-202 citations

pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine

Sponsors

Conditions

Phase 1

Phase 2

Related Papers